arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Alto Neuroscience, Inc.

ANRO
$27.49 ▼ -3.28 (-10.66%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
37
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Alto Neuroscience, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.2B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -9.9% ↘
FCF / Share $-0.46 ↗
Trailing P/E —
Price / Book 4.4x
FCF Yield —
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-26.24M
↓ -73.0% —
FCF / Share Free cash flow per share
$-0.46
↑ +45.1% —
Long-Term Debt Long-term obligations
$12.42M
↓ -10.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
19
Financial Health →
50
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 4 years · 15 quarters